JP2022515068A5 - - Google Patents

Info

Publication number
JP2022515068A5
JP2022515068A5 JP2021534757A JP2021534757A JP2022515068A5 JP 2022515068 A5 JP2022515068 A5 JP 2022515068A5 JP 2021534757 A JP2021534757 A JP 2021534757A JP 2021534757 A JP2021534757 A JP 2021534757A JP 2022515068 A5 JP2022515068 A5 JP 2022515068A5
Authority
JP
Japan
Prior art keywords
methylcellulose
anhydroglucose
anhydroglucose unit
active ingredient
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534757A
Other languages
English (en)
Japanese (ja)
Other versions
JP7535520B2 (ja
JP2022515068A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066712 external-priority patent/WO2020131784A1/en
Publication of JP2022515068A publication Critical patent/JP2022515068A/ja
Publication of JP2022515068A5 publication Critical patent/JP2022515068A5/ja
Application granted granted Critical
Publication of JP7535520B2 publication Critical patent/JP7535520B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534757A 2018-12-18 2019-12-17 メチルセルロースを含む徐放性組成物 Active JP7535520B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18213453 2018-12-18
EP18213453.6 2018-12-18
PCT/US2019/066712 WO2020131784A1 (en) 2018-12-18 2019-12-17 A sustained release composition comprising a methylcellulose

Publications (3)

Publication Number Publication Date
JP2022515068A JP2022515068A (ja) 2022-02-17
JP2022515068A5 true JP2022515068A5 (enExample) 2024-04-16
JP7535520B2 JP7535520B2 (ja) 2024-08-16

Family

ID=64744651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534757A Active JP7535520B2 (ja) 2018-12-18 2019-12-17 メチルセルロースを含む徐放性組成物

Country Status (4)

Country Link
US (2) US20220047498A1 (enExample)
EP (1) EP3897730A1 (enExample)
JP (1) JP7535520B2 (enExample)
WO (1) WO2020131784A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525831A (ja) 2022-08-02 2025-08-07 ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー アルギネートをベースとする放出調節組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2917104A1 (de) 1979-04-27 1980-11-06 Hoechst Ag Verfahren zur viskositaetserniedrigung von celluloseethern durch ozon und seine verwendung
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPS6225101A (ja) 1985-07-24 1987-02-03 Shin Etsu Chem Co Ltd 低重合度セルロ−スエ−テルの製造方法
US4734285A (en) 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US6261218B1 (en) 1998-12-01 2001-07-17 The Dow Chemical Company Process and apparatus for making low molecular weight cellulose ethers
EP1171471B2 (en) 1999-04-01 2009-07-08 Dow Global Technologies Inc. Enhanced gel strength methylcellulose
DE10141680B4 (de) 2001-08-25 2004-02-26 Clariant Gmbh Verfahren zur Herstellung niederviskoser Celluloseether durch sauer-oxidativen Abbau von gemahlenen und getrockneten Celluloseethern
CA2571554A1 (en) * 2004-06-28 2006-01-19 Alza Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8828426B2 (en) * 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
BR112014008692B1 (pt) * 2011-10-19 2022-01-18 Nutrition & Biosciences Usa 1, Llc Medicamento fluível ou ingerível por colher, alimento, ingrediente alimentício ou suplemento alimentar
IN2014CN02795A (enExample) * 2011-10-19 2015-07-03 Dow Global Technologies Llc
CN105358178B (zh) * 2013-07-17 2019-05-31 陶氏环球技术有限责任公司 用于施加到粘膜的包含甲基纤维素的组合物

Similar Documents

Publication Publication Date Title
KR102072371B1 (ko) 7-[4-(4-벤조[ｂ]티오펜-4-일-피페라진-1-일)부톡시]-1Ｈ-퀴놀린-2-온 또는 그 염을 함유하는 정제
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MA33726B1 (fr) Composes de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation
WO2015120110A3 (en) Novel pharmaceutical formulations
KR20150015209A (ko) 저분자 아세틸화 히알루론산의 제조방법 및 이의 용도
UY37577A (es) Dihidroimidazopiridindionas sustituidas
JP2022105649A5 (enExample)
JP2016108327A5 (enExample)
MX390201B (es) Nueva formulacion que comprende un derivado de bencimidazol
SA520412443B1 (ar) تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول
BR112022021748A2 (pt) Compostos e composições para inibir a atividade de hif2a e seus métodos de uso
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
RU2008147216A (ru) Жидкая лекарственная композиция
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112014032244A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças associadas com hiperplasia, neoplasia ou displasia, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
CN106236761A (zh) 一种包含稀有人参皂苷c‑k的稀有人参皂苷组合物
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
BR112016013974A8 (pt) composto, composição farmacêutica e uso de um composto.
JP2022515067A5 (enExample)
BRPI0611550A2 (pt) uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto
EA201170528A1 (ru) Производные 1-бутил-2-гидроксиаралкилпиперазина и их применения в качестве лекарственного средства против депрессии
CN114026105A (zh) 抗菌性氨基糖苷衍生物